ClinicalTrials.gg
CompletedNCT01222650Updated Jul 4, 2011

A Comparative Study of KSO-0400 in BPH Patients With LUTS

A Phase 2 interventional study of KSO-0400 and KSO-0400 in Benign Prostatic Hyperplasia (BPH), sponsored by Kissei Pharmaceutical Co., Ltd.. Completed at 1 site in Japan. Open to male participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2011-07-04.

Sponsored by Kissei Pharmaceutical Co., Ltd. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
400
Allocation
Randomized
Ages
50 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing silodosin in Prostatic Hyperplasia — 4 open to participants now, 4 under way, none of them phase 3. silodosin · Prostatic Hyperplasia.

Enrollment
7th of 19
400 · median 141
Phase 2
3 of 19
none open now
Registered
6th of 19
by date
Lead sponsor
1 of 19
Kissei Pharmaceutical Co., Ltd.

Among the 19 studies testing silodosin in Prostatic Hyperplasia, this one is the 7th largest by enrollment, is one of 3 in phase 2, and was the 6th registered.

Prostatic Hyperplasia

828 studies on the registry are indexed under Prostatic Hyperplasia; 179 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

4 of the 19 studies testing silodosin in Prostatic Hyperplasia are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About silodosin

silodosin: first FDA approval 2008 (RAPAFLO), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 102 Prostatic Hyperplasia studies recruiting now, 70 (69%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 50 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing silodosin in Prostatic Hyperplasia, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the efficacy and safety of KSO-0400 compared to placebo for the treatment of LUTS caused by BPH.

03

Conditions studied

  • Benign Prostatic Hyperplasia (BPH)

Browse trials for

Keywords

  • Benign Prostatic Hyperplasia
  • I-PSS
  • α1A-AR antagonist
04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • BPH patients with LUTS

Exclusion criteria

Exclusion Criteria:

  • Patients with a history of prostatectomy, intrapelvic radiation therapy, thermotherapy of prostate or prostatic hyperthermia
  • Patients with prostate cancer or suspected prostate cancer
  • Patients who have any cardiovascular, hepatic or renal disorder
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
400 participants

Study arms

  • Experimental
    KSO-0400 Low Dose

    Drug: KSO-0400

  • Experimental
    KSO-0400 High Dose

    Drug: KSO-0400

  • Experimental
    Silodosin

    Drug: Silodosin

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Change in I-PSS Total Score from baseline

    Time frame: Baseline and 12 weeks (LOCF)

Secondary outcomes

  1. Change in I-PSS Sub-score from baseline

    Time frame: Baseline and 12 weeks (LOCF)

  2. Change in QOL Score from baseline

    Time frame: Baseline and 12 weeks (LOCF)

  3. Change in Qmax (maximum urinary flow rate) from baseline

    Time frame: Baseline and 12 weeks (LOCF)

07

Study locations

1 site
  • Japan
    Kanto region, Japan
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 4, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01222650
First posted
Oct 18, 2010
Last update
Jul 4, 2011

Study contacts

Katsumi Hontani
study director · Clinical Development Dept.,Kissei Pharmaceutical Co., Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Silodosin

Start the discussion